Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
USD/CAD Price Forecast: Further correction to 20-day EMA might create buying opportunity

USD/CAD Price Forecast: Further correction to 20-day EMA might create buying opportunity

FXStreetFXStreet2026/07/03 09:06
By:FXStreet

The USD/CAD pair reflects a subdued performance near 1.4175 during the European trading session on Friday. The Loonie pair edges lower as the US Dollar (USD) faces selling pressure due to easing hawkish Federal Reserve (Fed) prospects.

In the European trade, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, trades 0.14% lower to near 100.70.

Weak US Nonfarm Payrolls (NFP) data for June has forced traders to reconsider hawkish Fed interest rate expectations. The data showed on Thursday that the economy created 57K fresh jobs in June, fewer than 110K estimates.

Going forward, investors will focus on the US ISM Services PMI data for June, which will be released on Friday.

On the Canadian Dollar (CAD) front, the currency has remained under pressure as oil prices have returned to pre-Middle East war levels, given that Canada is a net oil exporter. Oil prices have faced pressure as Oman has touted progress in indirect talks between the US and Iran.

USD/CAD technical analysis

USD/CAD edges lower to near 1.4179, but holds a clear bullish bias as price sits above both the 20-day and 50-day exponential moving averages (EMAs). The 20-day EMA at 1.4108 and the 50-day EMA at 1.3965 reinforce an underlying uptrend, while the Relative Strength Index (14), hovering just below the overbought region around 70, suggests persistent but stretched upside momentum.

On the downside, the pair could extend its correction to the 20-day EMA near 1.4110 as the US Dollar is under pressure. Given that the broader outlook is bullish, the odds are high that the correction move near the 20-day EMA would offer a buying opportunity to investors. On the upside, the pair could regain strength if it manages to break above the June 24 high at 1.4248; above that, the pair could extend its advance towards 1.4300.

(The technical analysis of this story was written with the help of an AI tool.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The "Outlier" Investment Art in the New Era of Berky

他山之石观投资2026/09/14 09:22
The "Outlier" Investment Art in the New Era of Berky

Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.

智通财经2026/09/14 09:12
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India

Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.

智通财经2026/09/14 08:57
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge

AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales

Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.

智通财经2026/09/14 08:41
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales